Canadian Health department and medical regulatory officials have given the green signal to launch a novel drug for the treatment of arthritis called Prexige which is described as a COX-2 inhibitor that seems to have no other side effects like cardiac complications which is associated with intake of other drugs used clinically for arthritis and of the same class .Those who have used other drugs in its class, such as Vioxx and Bextra have reported heart problems in the past. .
The pharmaceutical company Novartis announced the sanction of this COX-2 drug Prexige which will incidently be the first medicine of this class to be marketed in Canada for treatment of arthritis since all other drugs became notorious for raising the risk of heart problemsSource-Medindia
MST
